Test reports include:

**ASSAY TYPE**
FDA

**RESULTS**

| PD-L1 expression in tumor cells (TC) | 10% |
| PD-L1 expression in tumor-infiltrating immune cells (IC) | 35% |

**REFERENCE RANGE**

**Positive for PD-L1**
- \( \geq 25\% \) of tumor cells with membrane positivity for PD-L1 at any intensity above background
- \( \geq 25\% \) of tumor-associated immune cells with positivity for PD-L1 at any intensity above background, if immune cells present (ICP) is \( >1\% \)
- 100% of tumor associated-immune cells with positivity for PD-L1 at any intensity above background, if immune cells present (ICP)=1%

**Negative for PD-L1**
- \(< 25\% \) of tumor cells with membrane positivity for PD-L1 at any intensity above background
- \(< 25\% \) of tumor-associated immune cells with positivity for PD-L1 at any intensity above background, if immune cells present (ICP) is \( >1\% \)
- \(< 100\% \) of tumor associated-immune cells with positivity for PD-L1 at any intensity above background, if immune cells present (ICP)=1%

**INTERPRETATION**
PD-L1 POSITIVE

The interpretation of the test results, indicating whether a patient has a positive result and may be appropriate for PD-L1 inhibitor therapy positive for PD-L1.